SAREPTA THERAPEUTICS, INC.: 10-Q filed 2011-11-08
What SAREPTA THERAPEUTICS, INC. reported in its quarterly report filed 2011-11-08 (fiscal Q3 2011): 25 published measures, 72 facts as tagged in accession 0001193125-11-302239.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2011-11-08
- Fiscal period
- fiscal Q3 2011
- Accession
- 0001193125-11-302239 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SAREPTA THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 61,083,000 | USD | |
| At 2010-12-31 | 45,976,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 31,752,000 | USD | |
| At 2010-12-31 | -2,817,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 46,356,000 | USD | |
| At 2010-12-31 | 33,589,000 | USD | |
| At 2010-09-30 | 35,967,000 | USD | |
| At 2009-12-31 | 48,275,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -4,020,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -908,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | -308,554,000 | USD | 11393 |
| 2010-07-01 to 2010-09-30 | -7,293,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -24,533,000 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | -18,031,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | -224,566,000 | USD | 11393 |
| 2010-01-01 to 2010-09-30 | -13,321,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 973,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | 19,674,000 | USD | 11393 |
| 2010-01-01 to 2010-09-30 | 628,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 32,319,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | 297,167,000 | USD | 11393 |
| 2010-01-01 to 2010-09-30 | 2,467,000 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | -1,521,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | -26,245,000 | USD | 11393 |
| 2010-01-01 to 2010-09-30 | -1,454,000 | USD | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 2,445,000 | USD | |
| At 2010-12-31 | 2,070,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 2,454,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | 28,320,000 | USD | 11393 |
| 2010-01-01 to 2010-09-30 | 2,540,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -11,271,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -26,927,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | -321,965,000 | USD | 11393 |
| 2010-07-01 to 2010-09-30 | -3,797,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -19,194,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 51,945,000 | USD | |
| At 2010-12-31 | 37,838,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 26,531,000 | USD | |
| At 2010-12-31 | 45,857,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 7,899,000 | USD | |
| At 2010-12-31 | 1,311,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 4,698,000 | USD | |
| At 2010-12-31 | 3,980,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 4,267,000 | USD | |
| At 2010-12-31 | 3,224,000 | USD |
Common-stock repurchase payments
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1980-07-22 to 2011-09-30 | 289,000 | USD | 11393 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 15,610,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 48,161,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | 314,565,000 | USD | 11393 |
| 2010-07-01 to 2010-09-30 | 9,059,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 22,080,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 135,734,120 | shares | |
| At 2010-12-31 | 112,352,452 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 340,293,000 | USD | |
| At 2010-12-31 | 304,818,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 15,542,000 | USD | |
| At 2010-12-31 | 14,963,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 139,000 | USD | |
| At 2010-12-31 | 123,000 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 3,185,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 12,171,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | 100,573,000 | USD | 11393 |
| 2010-07-01 to 2010-09-30 | 3,440,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 11,017,000 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 763,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | 19,908,000 | USD | 11393 |
| 2010-01-01 to 2010-09-30 | 1,053,000 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 7,251,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 26,019,000 | USD | 273 |
| 1980-07-22 to 2011-09-30 | 13,411,000 | USD | 11393 |
| 2010-07-01 to 2010-09-30 | -3,496,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -5,339,000 | USD | 273 |
Inspect the source
- Entity
- SAREPTA THERAPEUTICS, INC. / CIK 0000873303
- Captured
- 2026-09-20T05:00:35.473Z
- SEC response SHA-256
73fbffcbdadfe28b857d7fca50ab4aac61e15003102807aade5f366cc35bb6b9
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000873303.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))